Phase 2 Trial of KM-819 Recruiting Patients After Promising Safety Data

Increasing doses of KM-819, a potential therapy being developed by Fascinate Therapeutics for Parkinson’s disease, showed a favorable safety profile in healthy older adults, according to data from the now-completed Part 1a of a Phase 2 trial. The placebo-controlled trial (NCT05670782), which was launched last year, is…

Phase 2 Trial Planned for KM-819 as Disease-modifying Therapy

Fascinate Therapeutics plans to launch a Phase 2 clinical trial into the safety and early efficacy of KM-819 as a potential therapy for Parkinson’s disease. This follows the approval by the U.S. Food and Drug Administration of Fascinate’s request for such a trial, in the form of an investigational new…

FDA Approval Sought to Begin Phase 2 Trial of KM-819

Fascinate Therapeutics has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial evaluating KM-819 as a potential therapy for Parkinson’s disease, the company announced in a press release. Parkinson’s disease is characterized by the death and dysfunction…

Kainos Begins Phase 1 Trial of Therapy for Parkinson’s Disease

The first patient has been dosed in a two-part Phase 1 clinical trial evaluating KM-819, Kainos Medicine’s potential disease-modifying treatment for Parkinson’s disease (PD), the company announced in a press release. The dose-escalation clinical trial (NCT03022799) will evaluate the drug’s safety, tolerability, and biochemical properties following single…